Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/15/2022* -- Results Q4 2021 -- -0.10 --
11/12/2021 -- Results Q3 2021 -0.01 -0.02 13.33%
08/13/2021 -- Results Q2 2021 -0.01 -0.12 88.70%
05/13/2021 -- Results Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/15/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/12/2021
Beat/Miss Upgrade
Return Since -44.49%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
URL https://www.chemomab.com
Investor Relations URL https://investors.chemomab.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Feb. 15, 2022
Last Earnings Release Nov. 12, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
23.57%
-75.07%
-21.88%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-7.66%
-16.57%
-18.49%
-37.81%
-14.87%
-82.54%
-46.06%
-27.53%
-6.20%
--
--
--
--
--
-34.12%
-74.92%
-10.00%
-23.29%
-20.19%
-50.98%
-13.20%
174.7%
103.2%
-64.49%
-14.88%
-54.80%
26.55%
-3.50%
-42.89%
-50.01%
79.44%
-79.35%
15.07%
As of January 21, 2022.

Profile

Edit
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
URL https://www.chemomab.com
Investor Relations URL https://investors.chemomab.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Feb. 15, 2022
Last Earnings Release Nov. 12, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits CMMB Tweets